Frontiers in Pharmacology | Pharmacoepidemiology

Original Research

Published on 26 Mar 2025

Community pharmacists’ views towards implementing a patient self-administered screening tool designed to identify risk of medication-related problems

in Pharmacoepidemiology

Mohammed S. Salahudeen
Ahmed Samy Saadeldean
Gregory M. Peterson
Behailu Terefe Tesfaye
Colin M. Curtain

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1531500

1,655 views

Original Research

Published on 20 Mar 2025

The interaction between a leflunomide-response methylation site (cg17330251) and variant (rs705379) on response to leflunomide in patients with rheumatoid arthritis

in Pharmacoepidemiology

Feng Zhao
Yulan Chen
Haina Liu
Lei Jin
Xin Feng
Bingbing Dai
Meng Chen
Qiao Wang
Yuxin Yao
Ruobing Liao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1499723

1,464 views

Systematic Review

Published on 18 Mar 2025

Correlation between UGT1A1 polymorphism and efficacy and toxicity of irinotecan in Chinese cancer patients

in Pharmacoepidemiology

Shuai Geng
Yulong Shen
Chen Zhang
Nan Wang
Xinyue Gao
Xinyu Luo
Ning Shi

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1563566

2,319 views
1 citation

Original Research

Published on 12 Mar 2025

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database

in Pharmacoepidemiology

Chang-Zhu He
Qin Qiu
Song-Jie Lu
Fu-Li Xue
Jun-Qiao Liu
Yu He

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1521358

9,104 views
5 citations

Original Research

Published on 12 Mar 2025

Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system

in Pharmacoepidemiology

Chengyu Zhu
Zhiwei Cui
Tingting Liu
Siyu Lou
Linmei Zhou
Junyou Chen
Ruizhen Zhao
Li Wang
Yingyong Ou
Fan Zou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1531514

3,677 views
5 citations

Original Research

Published on 10 Mar 2025

Development of a core outcome set for pharmacological interventions in osteoporosis among patients with diabetes mellitus: an international consensus study protocol

in Pharmacoepidemiology

Chao Wei
Xiaobin Wang
Zubing Mei
Jing Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1510968

2,413 views
2 citations

Original Research

Published on 10 Mar 2025

Signal detection and safety analysis of three tyrosine kinase inhibitors for HER-2 positive breast cancer: a retrospective study based on the FAERS database

in Pharmacoepidemiology

Xiting Tang
Chengliang Wang
Yanwei Li
Jing Tang
Guoping Zhang
Li Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1538881

3,164 views
1 citation

Review

Published on 10 Mar 2025

A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX

in Pharmacoepidemiology

Ralf J. Ludwig
Matthew Anson
Henner Zirpel
Diamant Thaci
Henning Olbrich
Katja Bieber
Khalaf Kridin
Astrid Dempfle
Philip Curman
Sizheng S. Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1516126

22,286 views
62 citations

Original Research

Published on 05 Mar 2025

Non-chemotherapy drugs inducing agranulocytosis: a disproportionality analysis based on the FAERS database

in Pharmacoepidemiology

Shanshan Wu
Lina Huang
Jiajia Chen
Xiaochun Xie
Shaokai Huang
Xiaojie Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1525307

3,912 views
3 citations

Original Research

Published on 19 Feb 2025

Impact of levetiracetam on direct oral anticoagulant level and outcomes among older Asian patients with atrial fibrillation

in Pharmacoepidemiology

Yu-Ting Huang
Tzu-Ling Chen
Yun-Lin Huang
Ching-Hua Kuo
Yu-Fong Peng
Sung-Chun Tang
Jiann-Shing Jeng
Chih-Feng Huang
Shin-Yi Lin
Fang-Ju Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1505665

3,321 views
3 citations

Original Research

Published on 18 Feb 2025

Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database

in Pharmacoepidemiology

Fang Wu
Siliang Wang
Xihui Xu
Weihui Zhang
Jie Zhou
Runyan Niu
Wenting Cai
Yonggong Yang
Mengying Liu
Jinping Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1459067

3,856 views
1 citation

Original Research

Published on 17 Feb 2025

Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis

in Pharmacoepidemiology

Long He
Jinwei Li
Xiong Cheng
Li Luo
Yilan Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1509561

6,662 views
5 citations

Original Research

Published on 13 Feb 2025

Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database

in Pharmacoepidemiology

Peng Jia
Yusen Zhou
Yuan Gao
Shangyu Wang
Jiangliu Yin
Yixiang Lian
Quanyou Lai

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1524159

4,397 views
5 citations

Original Research

Published on 13 Feb 2025

Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

in Pharmacoepidemiology

Fengqi Zhou
Haiou He
Jing Gao
Zhen Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1488469

2,603 views
1 citation

Original Research

Published on 11 Feb 2025

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system

in Pharmacoepidemiology

Shiyi Wang
Xiaojian Wang
Jing Ding
Xudong Zhang
Hongmei Zhu
Yihong Fan
Changbo Sun

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1436183

5,881 views
3 citations

Correction

Published on 07 Feb 2025

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database

in Pharmacoepidemiology

Xi-Feng Wang
Lu-Ri Bao
Ta-La Hu
Rui-Feng Xu
Wu-Niri Gao
Jing-Yuan Wang
Jian-Rong Zhao
Zhen-Li Fu
Shu-Fang Wang
Yan Meng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1558930

1,867 views
2 citations

Original Research

Published on 29 Jan 2025

Exploring the association between herbal medicine usage and drug-induced liver injury: insights from a nationwide population-based cohort study using SCCS in South Korea

in Pharmacoepidemiology

Taehyun Yang
Juhee Ahn
Sungho Won
Sanghun Lee

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1498124

7,475 views
2 citations

Original Research

Published on 24 Jan 2025

Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults

in Pharmacoepidemiology

Hao Li
Manxue Jiang
Xiaona Pan
Lingti Kong

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1524702

3,113 views
2 citations

Original Research

Published on 23 Jan 2025

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database

in Pharmacoepidemiology

Yalan Tian
Min Jin
Hong Ning

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1462510

3,247 views
2 citations

Systematic Review

Published on 23 Jan 2025

Global bibliometric analysis of traditional Chinese medicine regulating gut microbiota in the treatment of diabetes from 2004 to 2024

in Pharmacoepidemiology

Jieling Liang
Xiaojuan Lin
Xin Liao
Xi Chen
Ying Zhou
Lin Zhang
Yunyun Qin
Haoru Meng
Zhongwen Feng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1533984

3,420 views
1 citation

Original Research

Published on 10 Jan 2025

Overweight and glucose/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA adverse event reporting system

in Pharmacoepidemiology

Jinming Cao
Zhicong Chen
Yan Wang
Yunpeng Ma
Zhen Yang
Jian Cai
Zhijun Xiao
Feng Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1517546

5,510 views
2 citations

Editorial

Published on 10 Jan 2025

Editorial: Biologic drugs in immune-mediated inflammatory diseases, validation, drug-utilization, effectiveness, regulation, costs, and safety in the real-world

in Pharmacoepidemiology

Irma Convertino
Luciane Cruz Lopes
Nicole Pratt
Ylenia Ingrasciotta
Marco Tuccori

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1542453

2,307 views
1 citation

Original Research

Published on 09 Jan 2025

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database

in Pharmacoepidemiology

Xi-Feng Wang
Lu-Ri Bao
Ta-La Hu
Rui-Feng Xu
Wu-Niri Gao
Jing-Yuan Wang
Jian-Rong Zhao
Zhen-Li Fu
Shu-Fang Wang
Yan Meng

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1440907

6,329 views
2 citations

Original Research

Published on 08 Jan 2025

Safety of combined drug use in patients with cardiovascular and cerebrovascular diseases: an analysis based on the spontaneous reporting database of adverse drug reactions in Hubei Province

in Pharmacoepidemiology

Jia Wang
Yuhang Zhao
Zherui Chen
Rui Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1451713

2,637 views
1 citation

571 articles

articles

Community pharmacists’ views towards implementing a patient self-administered screening tool designed to identify risk of medication-related problems

The interaction between a leflunomide-response methylation site (cg17330251) and variant (rs705379) on response to leflunomide in patients with rheumatoid arthritis

Correlation between UGT1A1 polymorphism and efficacy and toxicity of irinotecan in Chinese cancer patients

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database

Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system

Development of a core outcome set for pharmacological interventions in osteoporosis among patients with diabetes mellitus: an international consensus study protocol

Signal detection and safety analysis of three tyrosine kinase inhibitors for HER-2 positive breast cancer: a retrospective study based on the FAERS database

A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX

Non-chemotherapy drugs inducing agranulocytosis: a disproportionality analysis based on the FAERS database

Impact of levetiracetam on direct oral anticoagulant level and outcomes among older Asian patients with atrial fibrillation

Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database

Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis

Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database

Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database

Exploring the association between herbal medicine usage and drug-induced liver injury: insights from a nationwide population-based cohort study using SCCS in South Korea

Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database

Global bibliometric analysis of traditional Chinese medicine regulating gut microbiota in the treatment of diabetes from 2004 to 2024

Overweight and glucose/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA adverse event reporting system

Editorial: Biologic drugs in immune-mediated inflammatory diseases, validation, drug-utilization, effectiveness, regulation, costs, and safety in the real-world

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database

Safety of combined drug use in patients with cardiovascular and cerebrovascular diseases: an analysis based on the spontaneous reporting database of adverse drug reactions in Hubei Province